Reproductive Hormone Regulator
Kisspeptin-10 is a reproductive signalling peptide that triggers the body's own testosterone and oestrogen production by activating the top of the hormonal cascade, preserving the natural feedback system rather than bypassing it. Backed by human clinical trials, it has also demonstrated measurable improvements in bonding, emotional processing, and prosocial behaviour.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
15 mg
Format
Injectable
Composition
5 mg/ml per ml
Kisspeptin-10 binds to the KISS1R (GPR54) receptor on GnRH-secreting neurons in the hypothalamic arcuate and anteroventral periventricular nuclei, stimulating robust, pulsatile GnRH release. This triggers LH and FSH secretion from the anterior pituitary, which in turn stimulates gonadal testosterone production in men and oestrogen/progesterone cycling in women. Kisspeptin-10 acts upstream of the HPG axis, providing a physiologically natural method of restoring hormonal signalling without directly suppressing endogenous production.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
Kisspeptin-10 acts at the apex of the reproductive hormone cascade: triggering GnRH release, which drives LH and FSH, which stimulate gonadal hormone production. This upstream action preserves the body's natural regulatory feedback loops, unlike direct testosterone or oestrogen administration.
Because Kisspeptin-10 stimulates the body's own testosterone production pathway rather than providing exogenous hormone, it does not suppress the HPG axis. It is studied as a post-cycle or testosterone-restoration agent for individuals whose natural production has been suppressed.
In women, Kisspeptin-10 regulates the LH surge that triggers ovulation and maintains progesterone and oestrogen cycling. Clinical trials have studied it for conditions including hypothalamic amenorrhoea, where GnRH pulsatility is disrupted.
Kisspeptin receptors are expressed in limbic brain regions, and clinical data documents an interesting secondary effect: Kisspeptin-10 administration increased bonding, emotional processing, and prosocial behaviour in human volunteers: suggesting a role beyond pure endocrine function.
Kisspeptin-10 has been studied in clinical IVF protocols as a trigger for oocyte maturation, with results comparable to standard hCG triggers and potentially reduced risk of ovarian hyperstimulation syndrome (OHSS).
The downstream hormonal effects of Kisspeptin-10 (elevated testosterone and oestrogen) naturally support libido, energy, and physical drive. The prosocial and emotional processing effects also contribute to desire at a neurological level.
Explore selected publications and registered trials on Kisspeptin, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Human randomized study
Exact Kisspeptin-10
Publication and key finding
Daily eight-hour subcutaneous Kisspeptin-10 infusions maintained higher gonadotropin secretion across 12 days, while acute administration also increased LH, FSH, and testosterone in healthy men.
European journal of endocrinology
Evidence type
Human clinical study
Exact Kisspeptin-10
Publication and key finding
Intravenous Kisspeptin-10 produced a rapid, dose-dependent rise in LH. Continuous infusion also increased testosterone, LH pulse frequency, and pulse size in healthy men.
The Journal of clinical endocrinology and metabolism
Evidence type
Human randomized study
Direct or closely related Kisspeptin evidence
Publication and key finding
In men with low sexual desire, Kisspeptin-54 altered activity in sexual-processing brain networks and was associated with increased physiological arousal and several desire-related measures.
JAMA network open
Evidence type
Human clinical study
Includes exact Kisspeptin-10
Publication and key finding
At the tested intravenous doses, Kisspeptin-10 and Kisspeptin-54 generated broadly similar gonadotropin responses in healthy men, while GnRH produced the stronger response.
Human reproduction (Oxford, England)
Evidence type
Human clinical study
Direct or closely related Kisspeptin evidence
Publication and key finding
In a small proof-of-concept study, Kisspeptin-10 increased LH secretion and pulse frequency in men with type 2 diabetes and mild biochemical hypogonadism, alongside higher testosterone.
Clinical endocrinology
5 selected studies from the wider trial library, in the order chosen for this product.
NCT01667406
NCT02956447
NCT04958109
NCT03286517
NCT03315325
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
Kisspeptin-10 has an excellent safety profile documented across multiple human clinical trials. As an endogenous peptide that acts on the body's own hormonal axis, it is highly biocompatible. The most commonly reported effects are mild and transient: hot flushes (consistent with LH/FSH surge), brief nausea in a minority of participants, and mild fatigue. No significant cardiovascular, renal, hepatic, or immune effects have been documented. In women, the potential for ovulation induction at effective doses warrants awareness. Unlike exogenous sex hormones, Kisspeptin-10 does not cause HPG axis suppression and does not carry the long-term risks associated with hormone replacement.
Other products from the same range
